Cogent Biosciences, Inc. (COGT) vs Erasca, Inc. (ERAS)
A side-by-side comparison of Cogent Biosciences, Inc. and Erasca, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
COGT
Cogent Biosciences, Inc.
$30.87HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
ERAS
Erasca, Inc.
$14.72HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — COGT vs ERAS
growth of $100 · dividends reinvested · last 5yCOGT +359.4% (+35.7%/yr)ERAS -15.5% (-3.3%/yr)COGT compounded faster over this window
Log scale — wide-divergence pair
COGT ERAS
COGT vs ERAS: by the numbers
- •COGT is the larger company ($5.27B vs $5.11B market cap).
Metrics side by side
Valuation
| Metric | COGT | ERAS |
|---|---|---|
| P/B ratio | 11.28 | 14.12 |
Profitability
| Metric | COGT | ERAS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -70.85% | -79.37% |
| ROIC | -50.09% | -38.03% |
Growth (annualized)
| Metric | COGT | ERAS |
|---|---|---|
| Total return CAGR (5Y) | 28.51% | -8.34% |
Frequently asked
- How have COGT and ERAS total returns compared?
- Over the past 5 years, COGT delivered 28.51% and ERAS delivered -8.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.